Physician profile
Luis Rojas
NPI 1487785838
$21,613.08
in general payments reported to CMS, 2019-2025
50 companies · $5,577 in 2025
The $5,577 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,023 · 2022: $4,276 · 2023: $4,063 · 2024: $5,675 · 2025: $5,577.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Education: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,092.24 |
| Education | $222.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,298.15 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $2,592.42 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,521.48 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,448.59 | 2021-2025 | Jardiance |
| Lilly USA, LLC | $1,428.49 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Amgen INC. | $1,415.24 | 2021-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $1,102.25 | 2021-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $982.68 | 2023-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $872.83 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Bayer Healthcare Pharmaceuticals INC. | $828.85 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $677.56 | 2021-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $449.41 | 2021-2025 | Eliquis, Camzyos, Cobenfy |
| Pfizer INC. | $398.99 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $350.98 | 2021-2025 | Verquvo, Delstrigo, Pifeltro |
| Viiv Healthcare Company | $350.07 | 2023-2025 | Dovato, Cabenuva, Apretude |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Rojas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.